cyrilzakka/clinical-trials huggingface dataset:
Role of Dutasteride in Treatment of Chronic Prostatitis

this placebo controlled study aims to evaluate the efficacy of Dutasteride in the management of Chronic prostatitis type 3.

Nonbacterial prostatitis refers to a condition that affects patients who present with symptoms of prostatitis without a positive culture for urine or expressed prostate secretions (EPS). With time our understanding of prostatitis was evolved to include a different clinical phenotype with a variety of voiding presentation and symptomatology rather than just inflammation and infection. The two main clinical presentations of prostatitis include pelvic pain and LUTS.

The National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK) proposed the first classification of prostatitis into 4 categories in 1995 that was later published in 1998. Bacterial prostatitis represented category I and III while nonbacterial prostatitis including chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) was categorized as category III that was further subdivided into class IIIa (inflammatory CPPS) and b (non-inflammatory CPPS). Category IV encompasses asymptomatic inflammatory prostatitis.

Shoskes et al, mentioned that inflammation and the upregulation of cytokine expression and release in the prostate secondary to an inflammatory process led to the presenting symptoms in such a condition. The recently introduced UPOINT phenotype categorization of CP/CPPS (Urinary, Psychosocial, Organ-specific, Infection, Neurological/Systemic, Tenderness of the skeletal muscles). This categorization shows up to 60% of men have at least prostate organ associated symptoms.

The prostate lies under the hormonal control of dihydrotestosterone (DHT); thus 5 alpha-reductase inhibitors (5ARIs) might be beneficial in the treatment of prostatitis. Dutasteride is a 5α-reductase inhibitor, and hence is a type of anti-androgen. It works by decreasing the production of (DHT) in certain parts of the body like the prostate gland. It inhibits all three forms of 5α-reductase and can decrease DHT levels in the blood by up to 98%.

5ARIs have been previously evaluated on a narrow scale in the management of prostatitis with promising results of safety and efficacy.

Eligibility Criteria:
Inclusion Criteria:

* patients aged between 40 and 70 years old, diagnosed with chronic prostatitis based on the presence of pelvic pain for ≥3 months of the preceding 6 months

Exclusion Criteria:

Patients with bacterial prostatitis

* documented site of infection along the urinary tract,
* urinary bladder tumors
* prostate cancer
* previous history of pelvic radiation or chemotherapy were excluded from our study.
Expression of BCRP in Icteric Patients

The expression of transporters involved in bile acid homeostasis is differentially regulated during obstructive cholestasis. Bile acids are also substrates of the drug efflux transporter breast cancer resistance protein (BCRP) that is highly expressed in the human intestine. Therefore we intend to analyze whether intestinal BCRP expression could be altered during cholestasis.

BCRP is capable of transport bile acids and may indicate that this transporter is involved in bile acid homeostasis. As an efflux pump, it could protect the enterocytes from potential toxic bile acid concentrations. During cholestasis, where the enterohepatic circulation is disrupted, there occurs an adaptive regulation of transporters for bile acids, bilirubin and cholesterol. These changes take place in liver, kidney, as well as in the intestine.

Using real-time RT-PCR analysis we determine BCRP mRNA expression levels in duodenal tissue of healthy subjects and cholestatic patients. BCRP protein levels will be determined by immunohistochemistry.

Healthy subjects and cholestatic patients are enrolled in the study after giving informed consent. Control subjects with an indication for a gastrointestinal tract endoscopy within a cancer-screening program and patients with obstructive cholestasis with an interventional endoscopic retrograde cholangiopancreatography (ERCP) are included in this study. During endoscopy four biopsy specimens are obtained from the distal part of the duodenum. Biopsies are immediately stored at -70°C until further processing.

Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of obstructive cholestasis (obstructive jaundice was defined on the basis of chemical parameters (bilirubin, g-glutamyltransferase, and alkaline phosphatase) and on imaging procedures (ultrasound and ERCP) demonstrating a dilated bile duct system)
* control subjects had an indication for a gastrointestinal tract endoscopy within a cancer-screening program

Exclusion Criteria:

-
A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions

This study will evaluate the effectiveness of Juvéderm® VOLIFT®™ with Lidocaine for dynamic radial cheek line skin depressions.


Eligibility Criteria:
Inclusion Criteria:

* Presence of dynamic radial cheek lines
* Agrees not to make any changes to skin care routines, or to have any facial procedures or treatments during the study

Exclusion Criteria:

* Previous facial surgery, tissue grafting, or tissue augmentation with silicone, fat, or other permanent, or semi-permanent dermal fillers or be planning to undergo any of these procedures during the study
* Undergone temporary facial dermal filler injections with any substance in the face in the 12 months prior to study entry
* Received botulinum toxin therapy of any serotype in any facial area within the previous 6 months agrees not to receive it during the study
Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies. In animal studies, xenon decreases the size of experimental myocardial infarction.

This 3-arm study will compare xenon, sevoflurane and a propofol-based total intravenous anaesthesia for maintenance of anaesthesia during coronary artery bypass graft surgery conducted with extra-corporeal circulation. Xenon and sevoflurane will be administered before and after extracorporeal circulation. Propofol will be administered during extracorporeal circulation in the three groups of patients.

The study will compare the postoperative myocardial damage observed 24 hours after surgery from blood levels of troponin I, a largely accepted biomarker of myocardial necrosis. The main hypothesis is that the myocardial damage observed after xenon administration will not be superior to the damage observed after sevoflurane administration (non-inferiority). The second hypothesis is that the myocardial damage observed after xenon administration will be inferior to the damage observed after total intravenous anaesthesia.


Eligibility Criteria:
Inclusion Criteria:

* coronary artery disease
* elective surgery, planned coronary artery bypass graft
* moderate hypothermia or normothermia
* cardiac arrest cold and warm cardioplegia
* normal of moderately impaired left ventricular systolic function
* written informed consent

Exclusion Criteria:

* pregnancy or child bearing potential
* ongoing treatment with nicorandil or sulfonylurea medication
* severe renal or hepatic dysfunction
* ongoing myocardial infarction or unstable angina
Influence of Post-thaw Embryo Culture Interval on Assisted Reproduction Success Rates

The transfer of frozen / thawed embryos has been routinely performed in the last 30 years as part of Assisted Reproduction treatment (ART). Currently, more than 50% of couples submitted to ART have surplus embryos eligible for freezing followed by transfer in subsequent cycles. Therefore the selection criteria for the thawed embryos to be transferred must be rigorous in order to maximize pregnancy and of live birth rates. Usually, the evaluation of the embryos before transfer can be performed based on blastomeres survival after a short culture period between thaw and embryos transfer, i.e., 2 to 5 hours, or based on embryo development over a prolonged period of culture (18h to 24h). Post-thaw embryo culture might have an impact on the recovery of mitosis and normal cellular functions. However, until now, there is no consensus in the literature on which post-thaw culture interval has a better impact on pregnancy and live birth rates. Also, blastocysts formation after freezing/thawing of embryos at cleavage stage may bring relevant information about post-thaw culture. Moreover, this strategy can be used as an alternative treatment. Therefore, the authors proposed this prospective randomized, triple-blind study to evaluate the impact of post-thaw embryo culture on the pregnancy and live birth rates.


Eligibility Criteria:
Inclusion Criteria:

* patients submitted to ART treatment due to infertility that had frozen embryos and need an embryo transfer after endometrial preparation and embryo thawing

Exclusion Criteria:

* patients that does not reach criteria for frozen embryo transfer (thin endometrium, bleeding, inappropriate use of hormones)
* difficult embryo transfer
* embryos that were frozen twice
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)

The objective of this trial was to evaluate whether Org 36286 treatment in any Phase IIa clinical development trial of Org 36286 for OI or COH in assisted reproductive treatment programs was safe for pregnant subjects and their offspring. Data from subjects who participated in Trials 38805 and 38807 and became pregnant were evaluated.

This was an open prospective follow-up trial to monitor pregnancy, delivery, and neonatal outcome of women who became pregnant during any Phase IIa clinical trial of Org 36286 for OI or COH for IVF. For this trial, no study specific assessments were required, but information obtained in standard practice was used.

Eligibility Criteria:
Inclusion Criteria:

* Subjects taking part in any clinical development trial of Org 36286 for OI or COH for IVF in Phase IIa;
* Ongoing pregnancy confirmed by ultrasonography (USS) at or beyond 12 weeks of gestation;
* Able and willing to give written informed consent.

Exclusion Criteria:

* None
Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy

The aim of this study was to evaluate the effect of exogenous ALC on the both physical and mental fatigue in mild and moderate encephalopatic patients.


Eligibility Criteria:
Inclusion Criteria:

* 1) Chronic hepatitis with spontaneous manifest HE (mental state grade 1 or 2 according to the West Haven criteria) and an NCT-A performance time \>30 seconds;
* 2) Hyperammonemia (venous ammonia concentration \>50 mmol/L);
* 3) Cooperative, hospitalised, adult patients with liver cirrhosis diagnosed by clinical, histological and ultrasonographic findings (reduced dimensions of the liver as well as splenomegaly) and oesophageal varices at stage II and III observed by endoscopy.

Exclusion Criteria:

* 1) Major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial peritonitis;
* 2) Acute superimposed liver injury;
* 3) Patient with other neurological disease and metabolic disorders, diabetes mellitus, unbalanced heart failure and/or respiratory failure or end-stage renal disease;
* 4) Alcoholic -toxic cirrhosis because toxic brain damage may interfere with the assessment of HE;
* 5) Severe HE;
* 6) Administration of anti-HE medications such as neomycin, branched-chain amino acids;
* 7) Any additional precipitating factors such as high protein intake (additional high-protein meals), constipation or intake of psycho stimulants, sedatives, antidepressants, benzodiazepines, or benzodiazepines-antagonists (flumazenil), beta-adrenergic blockers, neuromuscular blocking agents, certain antibiotics;
* 8) Patients with fever, sepsis or shock were also excluded to avoid variations caused by body temperature;
* 9) Illiteracy.
Evaluation of Neuropathic Pain in the Context of Clinical Symptoms, Quantitative Sensory Tests and Imaging With FMRI

This study is planned to evaluate patients with upper extremity neuropathic pain due to cervical radiculopathy with clinical symptoms, Quantitative Sensory Testing(QST) and Functional Magnetic Resonance Imaging(fMRI). Patients with similar charactheristics will be grouped and comparisons will be conducted in fMRI results, as well as QST.

Neuropathic pain is a type of pain which usually accompanies injuries or conduction defects in the central or peripheral nervous system, as well as receptors. Unlike the other types of pain, neuropathic ones are more resistant to therapy and prone to be chronic.

In recent years, there are many novel techiques to assess the neurological status and create standardized test protocols. One of these techiques is QST(Quantitative Sensory Testing). QST is a specific type of sensory examination, usually done through computerized stimuli of heat, cold or vibration, or specific test equipment. There are many types of QST protocols around the world, and their results can also be expressed as phenotypes through statistics. While there are 3 types of pain phenotypes with the 13 item QST protocol suggested by German Neuropathic Pain Research group(DFNS), all patient groups can be classified differently as well, according to the common findings they express. These different phenotypes are also shown to have different responses to the different pain treatments. Such differences are usually attributed to the different mechanisms and fibers underlying the pathogenesis.

While patients show differences in QST results, evidence for the correlation between these variables and clinical symptoms of the patients are still scarce. Moreover, it is still yet to be known if these differences have a central origin as well as the peripheral mechanisms.

Functional Magnetic Resonance Imaging(fMRI) is a method to evaluate cerebral functions. It is mainly based on the blood flow changes that occur locally in regions that are in function\[5\]. As a result of the increased blood flow, the oxygen concentration also increases, creating a signal response called BOLD(Blood Oxygen Level Dependent) response. Since different types of pain are conducted through different fibers and pathways, it is also probable that they might show changes in cortical response as well.

In this study, the aim is to find whether QST results are correlated to clinical symptoms and pain properties of the patients, and these changes are related to the changes in the central nervous system

Eligibility Criteria:
Inclusion Criteria:

Adult patients with upper extremity neuropathic pain due to radiculopathy Duration of \>1 month Unilateral extremity pain

Exclusion Criteria:

* Severe cognitive impairment
* Unstable systemic comorbidity
* Presence of pacemaker or deep brain stimulation
* Implants that aren't compatible with MRI
* Claustrophobia
* Complete or near complete loss of sensation
* Brain injury or presence intracranial lesions
Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma

The aim of this study is to evaluate the hepatic perfusion computer tomography and dual energy computer tomography in the assessment of tumor characterization of Hepatocellular carcinoma in patients with resectable Hepatocellular carcinoma by comparing the quantitative parameters computer tomography obtained with the pathological data of the surgical specimens.

Dual-energy computer tomography and perfusion computer tomography (General Electric revolution Hight definition Gemstone™ Spectral Imaging) will be performed in all patients. Iodine concentration and quantitative perfusion parameters of the Hepatocellular carcinoma and surrounding liver parenchyma data will be compared with the pathological results.

Eligibility Criteria:
Inclusion Criteria:

* A diagnosis of Hepatocellular carcinoma made according to the guidelines of the American Association for the study of the Liver
* Affiliation to a national health insurance
* An indication for hepatic resection during the decision-making stage
* A request for a pre-operative Computer Tomography in our radiology unit
* An affiliation to a social security
* Informed consent given by the patient

Exclusion Criteria:

* Previous treatments of Hepatocellular carcinoma (medicated or surgical)
* Patient under tutorship or curatorship
* Pregnant or lactating woman
Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma

Anti-apoptotic proteins from the Bcl-2 family are known to play a key role in oncogenesis and are overexpressed in myeloma cells. Studies have shown that dendritic cells exposed to proteasome inhibition present exogene antigens better than unexposed dendritic cells. Patients with relapse of multiple myeloma will be offered vaccination with peptides derived from antiapoptotic proteins from the Bcl-2 family in combination with an immunostimulatory adjuvant. The vaccination will be given in relation to treatment with the proteasome inhibitor bortezomib.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of multiple myeloma
* tissue type of HLA-A1, HLA-A2 or HLA-A3
* Performance status \< 2
* Adequate bone marrow - renal and liver function
* written informed concent

Exclusion Criteria:

* candidate for bone marrow transplantation
* other malignancies than multiple myeloma
* other significant medical disease (heart-, lung or liver disease or diabetes)
* allergy
* active autoimmune disease
* treatment with immunosuppressive drugs
* treatment with other experimental drugs
* uncontrolled hypercalcemia
Myocardial Infarction Triggers and Onset in Jordan Study 2

A previous study (MINTOR 1) found that 43% of ST elevation myocardial infarction (STEMI) patients in Jordan had a triggering events. Fifteen years later, with changing demographics and in the post covid-19 time, we believe that triggered acute myocardial infarction might have changed in incidence and nature of the triggering events.

The onset of acute ST elevation myocardial infarction (STEMI) is a complex interplay of internal circadian factors and external physical and emotional triggers. These interactions may lead to rupture of an often nonocclusive vulnerable atherosclerotic coronary plaque with subsequent formation of an occlusive thrombus. The onset of MI has a distinct pattern, with peak incidence within the first few hours after awakening, on certain days of the week, and in the winter months. Physical and emotional stresses are important triggers of acute cardiovascular events including MI. Triggering events, internal changes, and external factors vary among different geographical, environmental, and ethnic regions. Life-style changes, pharmacotherapy, and psychologic interventions may potentially modify the response to, and protect against the effects of triggering events.

MINTOR 1 showed that 43% of 900+ Jordanians with STEMI were exposed to a physical or emotional triggers before the onset of the heart attack. It was also found that Friday was the day of the week that witnessed more MIs that other days of the week and that 55% of MIs occurred in the early morning hours.

It is largely unknown if the frequency and types of triggers, onset time of MI, day with peak of MI incidence have changed over time in Jordan with changing population demographics, especially in the post Covid-19 times. These patients will be followed up for 3 years for occurring of incident vascular events.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years and above.
* Documented acute ST elevation myocardial infarction.
* Willing to sign an informed consent.
* Available contact numbers for a 3-year follow up

Exclusion Criteria:

* Unwilling to sign an informed consent.
Influence of Gender on Interaction of Propofol and Dexmedetomidine

The purpose of this study is to determine the effect of gender on pharmacodynamic interaction of propofol and dexmedetomidine, exploring the effect of gender on propofol unconsciousness median effective concentration with different dose dexmedetomidine.

60 cases male patients were randomly divided into four groups,and 60 female patients were also randomly divided into four groups.In each group, dexmedetomidine target plasma concentration are 0,0.4,0.6,0.8 ng/ml. Dexmedetomidine administered 15 min before target controlled infusion of propofol. The propofol infusion is started to provide a target effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness when the effect-site concentration and target concentration are equilibrium.

Eligibility Criteria:
Inclusion Criteria:

1. Weight:18≦ BMI≦25
2. Written informed consent from the patient or the relatives of the participating patient.

Exclusion Criteria:

1. A previous history of intolerance to the study drug or related compounds and additives.
2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.
Corneal Oxygen Uptake With Apioc Contact Lenses

The purpose of this research is to determine if a new investigational contact lens shape allows the eye to get more oxygen.


Eligibility Criteria:
Inclusion Criteria:

1. Provide informed consent.
2. Appear willing and able to adhere to instructions set forth in the protocol.
3. Be between the ages of 18 and 45.
4. Be an experienced contact lens wearer.
5. Be an eyecare clinician or clinician-in-training.
6. Flat and steep keratometry readings within 40 to 50D.
7. Clear, healthy corneas with no irregular astigmatism.
8. Normal, healthy conjunctiva in both eyes.
9. Be able to provide corneal topography measurements.
10. Be able to provide manifest refraction measurements.

Exclusion Criteria:

1. Irregular corneal astigmatism.
2. Use of topical or systemic antihistamines within the previous week.
3. Use of topical ophthalmic drops within the previous two days.
4. History of corneal surgery.
5. Currently pregnant or lactating.
6. Systemic disease that would interfere with contact lens wear.
7. Previous diagnosis of dry eye syndrome.
Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of Spiders

Investigation of the efficacy of a gamified augmented reality exposure app in individual with fear of spiders.

The study will be conducted as a randomized controlled between subject trial. The study consists of two visits and a home training for one group. 60 participants between 18 and 40 years with clinical or subclinical fear of spiders will take part in the study.

All assessments of outcome will be conducted on one visit for each participant, including an in vivo BAT. The experimental group will participate in a home training with the app, spanning over two weeks (6x30-minutes sessions), whereas the control group will not receive any treatment (untreated comparison group).

Six weeks after the first visit all participants undergo the assessments of outcome, including a second in vivo BAT. The BAT will take place 4 weeks after completion of the home training. This design allows a direct comparison and therefore an estimation of the efficacy of the gamified AR exposure therapy.

Eligibility Criteria:
Inclusion Criteria:

* Fear of spiders
* BAT score before exposure between 1-8
* Physically healthy
* Fluent in German

Exclusion Criteria:

* BDI-II sumscore \>=20 and/or item 9 \>=1
* Concurrent psychotherapy or pharmacotherapy
* Previous exposure-based therapy for spider phobia
* Parallel participation in another study
* Chronic medication intake (except oral contraceptives)
* Medication intake before visits (less than 24h)
* Alcohol intake before visits (less than 12 h)
* Cannabis or other psychoactive substances (including benzodiazepines) intake before visits (less than 5 days)
* For women: Current pregnancy